首页> 外文期刊>Ophthalmic Surgery and Lasers >Treatment of total hyphema with relatively low-dose tissue plasminogen activator.
【24h】

Treatment of total hyphema with relatively low-dose tissue plasminogen activator.

机译:用相对低剂量的组织纤溶酶原激活剂治疗总前房积血。

获取原文
获取原文并翻译 | 示例
           

摘要

The purpose of this study is to investigate the efficacy of tissue plasminogen activator (tPA) in the treatment of total hyphema following ocular trauma or intraocular surgery. Three patients (3 eyes) representing unresolved total hyphema for more than 5 days and uncontrolled high intraocular pressure received intracameral injections of 10 microgram of recombinant tPA. Intracameral tPA injection resulted in complete resolution of hyphema in all 3 eyes. Resolution occurred mostly within 24 to 48 hours after injection. Possible side effects of tPA injection, such as increased intraocular pressure and corneal edema, were not observed. However, 1 eye had vitreous hemorrhage after repeated injections of tPA. Intracameral injection of tPA seems to be a safe and effective method for the treatment of unresolved total hyphema. However, repeated intracameral tPA injections may cause unwanted complications such as vitreous hemorrhage.
机译:这项研究的目的是研究组织纤溶酶原激活物(tPA)在眼外伤或眼内手术后治疗总前房积血的疗效。代表超过5天未解决的全部眼前眼和不受控制的高眼内压的三名患者(3只眼)接受了10μg重组tPA的前房内注射。前房内tPA注射可完全消除所有三只眼的前房积血。解决方法主要发生在注射后24至48小时内。未观察到tPA注射的可能的副作用,例如眼内压升高和角膜浮肿。然而,重复注射tPA后,有1只眼睛有玻璃体出血。前房内注射tPA似乎是治疗未解决的总前房积血的一种安全有效的方法。但是,反复进行前房内tPA注射可能会导致不必要的并发症,例如玻璃体出血。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号